Welcome to Business Upturn’s live coverage of the Indian stock market on Thursday, 25 September 2025. The trading session is expected to remain stock-specific as several companies announced key developments.
In focus today will be Glenmark Pharma, Lupin, Apollo Hospitals, NTPC, Tata Steel, Cipla, Dalmia Bharat, Tata Motors, Newgen Software, Birla Corp, Indegene, Sterlite Tech, TGV Sraac, Piccadily Agro, Sancode Technologies, Ethos Limited, Quality Power, Ipca Laboratories, Autoriders International, GPPL, Panacea Biotec, Paradeep Phosphates, Asahi India Glass, TBO Tek, Veedol, Hindustan Copper, Oil upstream stocks, Fineotex Chemical, IFB Industries, Dr. Reddy’s, Camlin Fine Sciences, Torrent Pharma, Polycab India, Piramal Enterprises, Akzo Nobel, GPT Infraprojects, Hubtown, REC, Eveready, Crisil, Bank of Baroda, Mastek, Le Travenues, GMDC, HBL Engineering, Emkay, MSP Steel, Knowledge Marine, Adtech Systems, Evans Electric, 3i Infotech, Chandra Prabhu International, Nazara Technologies, PVV Infra, R M Drip, and more.
Indian equities are set for a cautious start today as mixed global cues keep sentiment muted. At the pre-open session, GIFT Nifty was quoting at 25,078, down 34 points or 0.14%, indicating a tepid opening for domestic markets.
Global market trends remain mixed. Asian equities opened on a subdued note, though buying interest emerged at lower levels. U.S. index futures were trading in the green after Wall Street closed lower overnight, with investors awaiting weekly jobless claims data and the Federal Reserve’s preferred inflation gauge later this week.
Sectoral focus may remain on metals, healthcare, selective construction, and energy stocks, which are expected to see active trading during the session.
Stay tuned as we bring you real-time Sensex, Nifty, and stock-specific updates, corporate announcements, and intraday market action throughout the day.
Disclaimer: This is a live market news coverage compiled from company announcements, exchange filings, and media reports. The information provided is for informational purposes only and should not be construed as investment advice or a recommendation to buy or sell any security. Readers are advised to consult their financial advisor before making any investment decisions. Business Upturn and the author are not responsible for any losses arising from investment decisions based on this coverage.
